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Abstract
In the vast majority of cystic fibrosis (CF) patients, deletion of residue F508 from CFTR is the cause of disease. F508 resides in
the first nucleotide binding domain (NBD1) and its absence leads to CFTR misfolding and degradation. We show here that
the primary folding defect arises during synthesis, as soon as NBD1 is translated. Introduction of either the I539T or G550E
suppressor mutation in NBD1 partially rescues DF508 CFTR to the cell surface, but only I539T repaired DF508 NBD1. We
demonstrated rescue of folding and stability of NBD1 from full-length DF508 CFTR expressed in cells to isolated purified
domain. The co-translational rescue of DF508 NBD1 misfolding in CFTR by I539T advocates this domain as the most
important drug target for cystic fibrosis.
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Introduction
The Cystic Fibrosis Transmembrane conductance Regulator
(CFTR) is a multi-spanning membrane protein that not only
functions as a cAMP-dependent chloride channel but also interacts
with other proteins to mediate ion conductance at the cell surface
of lung and intestinal epithelial cells [1,2,3]. The 1,480 amino
acids form five major domains: two membrane-spanning domains
(MSD1 and MSD2), two cytosolic nucleotide-binding domains
(NBD1 and NBD2), and a unique cytosolic regulatory domain (R-
domain) that is not found in other members of the ATP-binding
Cassette (ABC) Transporter C class.
More than 1,500 mutations found in the gene encoding CFTR
lead to cystic fibrosis, the most common lethal genetic disease
amongst Caucasians. The most frequent CF-causing mutant,
DF508, lacks a phenylalanine in NBD1; it is efficiently retained in
the ER [4] and almost completely degraded by the proteasome via
ER associated degradation [5,6].
Structural models of CFTR [7,8,9] place F508 at the interface
between NBD1 and the 4
th intracellular loop (ICL4), located
within MSD2. Studies on DF508 CFTR folding showed that the
side chain loss impaired domain-domain interactions within
CFTR [10], and that DF508 increased protease susceptibility of
NBD2 and MSD1 in a post-translational fashion [11,12]. On the
other hand, in vitro the DF508 mutation does affect NBD1 folding
[10,13,14] directly, suggesting that deletion of F508 may induce
several folding defects, which eventually cause ER retention and
degradation.
DF508 CFTR can be rescued from retention in the ER by lowering
temperature of cells expressing DF508 CFTR [15], by addition of
chemical chaperones [16,17,18], or by introducing suppressor
mutations [19]. Teem and coworkers [19] identified two mutations,
G550E and I539T, that both significantly increased plasma membrane
levels of DF508 CFTR and improved channel activity [19,20,21].
We have established a CFTR folding assay that allows analysis
of co- and post-translational folding of CFTR. Using limited
proteolysis performed directly on newly synthesized radiolabeled
nascent chains of increasing lengths, full-length CFTR, and
isolated domains, but also on purified NBD1 domain, in parallel
with biophysical studies, we explored when and where in the full-
length structure DF508 CFTR misfolds. We found that DF508
CFTR affects both cell biological and biophysical stability of the
NBD1 domain, already co-translationally and independent of
other domains. Introduction of I539T, but not the G550E
suppressor mutation, counteracted all folding defects within
NBD1, whereas both mutations rescue CFTR trafficking to the
cell surface. As mouse CFTR already has a threonine in the
human I539 position [19], this residue may act as natural
intragenic, intradomain suppressor and hence may contribute to
the somewhat milder nature of lung disease in CF mice [22].
Results
Small conformational defect in DF508 CFTR
To determine conformational differences between wild-type and
mutant CFTR, we used limited proteolysis of radiolabeled CFTR
PLoS ONE | www.plosone.org 1 November 2010 | Volume 5 | Issue 11 | e15458with a selection of proteases. Wild-type and DF508 CFTR were in
vitro translated and translocated into the ER membrane of
digitonin-permeabilized human HT1080 cells in the presence
of
35S-methionine/cysteine. After 60 min of translation these
newly synthesized radiolabeled proteins were solubilized in Triton
X-100 and subjected to limited proteolysis using a concentration
range of proteinase K to probe their conformation (Figure 1A).
This assay is based on the relative protease resistance of folded
domains compared to unstructured or misfolded regions
[11,12,23,24,25]. Because CFTR is the only radiolabeled protein
in this assay we directly analyze all protease resistant fragments on
SDS-PAGE that originate from the complete protein without the
caveats of methods requiring immunoprecipitations [24].
Comparing the proteolytic patterns of wild-type and DF508
CFTR we found that their protease susceptibility patterns were
very similar (Figure 1A). Only a single proteinase K resistant
fragment of ,25 kDa that was present in wild-type CFTR
(Figure 1A, lanes 2–4, b) was absent in DF508 CFTR (Figure 1A,
lanes 7–9, b). Quantification of the relative intensities of all
Proteinase K resistant fragments (5 mg/ml) confirmed this
observation (Figure 1B, same symbols as in Figure 1A). In
addition a more subtle conformational change in DF508 CFTR
appeared (Figure 1B, *) and some smaller fragments (Figure 1B,]),
suggestive of increased proteolytic susceptibility of the mutant.
Because the assay is capable of detecting substantial misfolding of
CFTR [24], these results suggest that DF508 CFTR had profound
conformational perturbations although most of the structure was
remarkably similar to that of wild-type CFTR.
DF508 affects CFTR structure locally
To identify the domain origin of the protease resistant fragments
we previously used a series of C-terminally truncated CFTR
constructs with stop codons behind each subsequent domain [24].
The protease resistant fragment of ,25 kDa that was lost in
DF508 CFTR did arise in constructs truncated behind NBD1 or
downstream, but not in the shorter construct truncated behind
MSD1 (data not shown), implying that this fragment related to
NBD1. A polyclonal antibody raised against NBD1, with three
prominent epitopes in NBD1, (Mr. Pink) specifically immunopre-
cipitated the ,25 kDa fragment from a total pool of protease
resistant fragments (Figure 1C, lanes 3 and 4), whereas an
antibody against the R-region did not (Figure 1C, lanes 5 and 6).
Our results demonstrate that folding mutation DF508, which
efficiently retains CFTR in the ER, caused misfolding primarily in
NBD1, the domain in which it resides.
DF508 destabilizes isolated NBD1 both in vitro and in vivo
To find out whether DF508 misfolds NBD1 also in the absence
of the other CFTR domains and out of biological context, we
analyzed in vitro translated wild-type and DF508 NBD1 domain in
our assays and compared their protease susceptibilities. Wild-type
and mutant NBD1 were equally susceptible to proteinase K
(Figure 2A, #). With increasing protease concentrations several
smaller resistant fragments appeared, which were more rapidly
degraded in DF508 NBD1 (Figure 2A, marked by symbols). The
prominent ,25 kDa band present in wild-type NBD1 (Figure 2A,
b) was almost completely digested in DF508 NBD1. We found
Figure 1. Minimal and local misfolding of DF508 CFTR. (A) Both CFTR and DF508 CFTR were translated in vitro in the presence of
35S-
methionine and cysteine and semi-permeabilized HT1080 cells for 60 min. Cells containing radiolabeled CFTR proteins were washed, lysed in Triton
X-100, and prepared for limited proteolysis using increasing concentrations of proteinase K. The proteolytic digests were analyzed by 12% SDS-PAGE.
The conformational difference between wild-type CFTR and DF508 CFTR is indicated by an arrowhead. (B) Relative intensities of all protease resistant
fragments from a total 5 mg/ml Proteinase K digest, as in Figure 1A, were determined by total lane quantitation (Quantity One software Biorad). The y-
axis represents electrophoretic mobility in 12% SDS-PA gel and the x-axis the relative intensity of the protease resistant fragments. The horizontal
lines indicate the structural differences as described in A. The horizontal line indicated with an asterisk represents yet unidentified changes in the
proteolytic pattern as a result of the DF508 mutation. The bracket represents small proteolytic fractions detected in both mutants. (C) Wild-type and
DF508 CFTR were synthesized as in a, were subjected to 5 mg/ml proteinase K and NBD1-originated fragments were immunoprecipitated with
polyclonal antibodies directed against NBD1 (Mr Pink) or against the R-region (G449). Arrowhead marks the NBD1-related fragment.
doi:10.1371/journal.pone.0015458.g001
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able (when analyzed side by side; not shown) from the fragment
lost in the digests from full-length DF508 CFTR (Figure 1A, b).
Two other protease resistant fragments showed decreased intensity
in DF508 NBD1 digests as well: of ,27 kDa (Figure 2A, *,
compare lanes 2 and 7) and ,17 kDa (only visible in longer
exposures, see below).
The trypsin digests showed a similar result: NBD1 was equally
susceptible to the protease irrespective of the F508 deletion, but
the resulting triplet of protease resistant fragments was again more
sensitive in DF508 (Figure 2B, lanes 8–10,]) than in wild-type
NBD1 (Figure 2B, lanes 3–5). We found the ,17 kDa protease
resistant fragment only in the wild-type NBD1 proteolysis pattern
(Figure 2B, N). Immunoprecipitation with an NBD1-specific
monoclonal antibody (7D12) (see Materials and Methods) clearly
confirmed the NBD1-identity of these fragments and showed that
the 17 kDa fragment was absent in the trypsin digest of DF508
NBD1 (Figure 2C). Antibody mapping showed that the 25 kDa
NBD1 fragment that is protease susceptible in DF508 was
recognized by antibodies Mr. Pink (directed against various
epitopes within NBD1) and 7D12 (epitope 531–540), but not by
3G11 (epitope 396–405) (Figure 2D, b), 10B6.2 (epitope 399–408,
not shown), or G449 (raised against R-region residues 693–716
but also recognizing C-terminal residues in NBD1, not shown).
This suggests that the 25 kDa NBD1 fragment had lost its N- and
C-termini and that the NBD1 core structure was destabilized by
deletion of F508. Irrespective of protease used, proteolytic
fragments of DF508 NBD1 were less stable than fragments of
wild-type domain. We therefore concluded that deletion of F508
destabilizes isolated NBD1 core domain in biological context as
has been shown before in vitro [10,13,14].
Because full-length CFTR DF508 is degraded efficiently by the
proteasome and because deletion of F508 altered NBD1
conformation directly, we anticipated that this conformational
change would affect biological stability of the NBD1 domain in
intact cells. CHO cells were transfected and pulse-labeled to follow
NBD1 stability with time (Figure 2E). Wild-type NBD1 was
relatively unstable already as only ,30% of pulse-labeled protein
was left after 4 hours of chase, but degradation of DF508 NBD1
indeed was significantly faster with 90% of molecules degraded
after 4 hours (Figure 2E).
The in vitro translation mimics in vivo conditions in many
important regards: the ER is relatively intact and the reticulocyte
lysate used as source of cytosol is full of chaperones and other
folding enzymes, which exert their effect on newly synthesized full-
length CFTR but also on isolated NBD1. If bound tightly,
Figure 2. The effect of DF508 mutation on NBD1 alone. (A) Wild-type and DF508 NBD1 were in vitro translated for 30 min, treated with
indicated proteinase K concentrations as in Figure 1, and analyzed using 15% SDS-PAGE. The full length NBD1 domain is indicated by ‘‘#’’, the
asterisk (*) indicates the 27 kDa fragment, arrowhead (b) indicates the 25 kDa fragment. (B) Similar experimental conditions as described in A, but
using TPCK-trypsin as protease. A bracket (]) marks the triplet of protease resistant fragments and the dot (N) marks the 17 kDa fragment. (C) Wild-
type and DF508 NBD1 were synthesized as in A, treated with 100 mg/ml trypsin, and fragments were immunoprecipitated with antibody 7D12 against
NBD1. Fragments are labeled similar as in B. (D) Wild-type NBD1 was synthesized as in A, treated with 25 mg/ml proteinase K, and fragments were
immunoprecipitated with the 7D12, 3G11 and Mr Pink antibody, recognizing specific epitopes within NBD1. Fragments are labeled similar as in A. (E)
CHO cells expressing wild-type or DF508 NBD1 were pulse-labeled with
35S-methionine and cysteine for 5 min and chased for indicated times. NBD1
was immunoprecipitated using polyclonal antibody Mr Pink and analyzed using 15% SDS-PAGE. NBD1 indicated by ‘‘#’’. (F) Purified human wild-type
and DF508 NBD1, indicated by ‘‘#’’, were incubated with 2 mg/ml Proteinase K for 0, 2, 5, 10 and 30 minutes at room temperature. Proteolytic digests
were separated using 15% SDS-PAGE and visualized by silver staining. Asterisk (*) and arrowhead (b) indicate 27 and 25 kDa fragments resp., and are
similar as in A. The open arrowhead (,) indicates a protease resistant background band in the purified DF508 NBD1.
doi:10.1371/journal.pone.0015458.g002
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the CFTR domains as well by shielding protease cleavage sites. To
distinguish the role of cellular context in NBD1 misfolding from a
direct effect of the DF508 mutation on NBD1, we examined the
stability of purified human NBD1 domains in the absence of any
other proteins. We used the same limited proteolysis folding assay,
but instead fixed the protease concentration and varied the time of
digestion at room temperature. We subjected purified wild-type
and DF508 NBD1 to 2 mg/ml proteinase K and analyzed all
fragments on a silver-stained SDS-PA-gel (Figure 2F). The
resulting proteolytic pattern was remarkably similar to the pattern
of newly synthesized in vitro translated NBD1 (Figure 2A). Again
the wild-type NBD1 showed a protease resistant fragment of
25 kDa while the corresponding 25 kDa fragment of DF508
NBD1 was quickly degraded (Figure 2F, b, compare lanes 3&4
with lanes 8&9). The smaller fragments below 15 kDa represent
degradation products of the destabilized 25 kDa core domain of
DF508 NBD1. These fragments are not found in digests of in vitro
translated NBD1 because they may lack radiolabeled methionines
and cysteines. These results clearly showed that deletion of F508
induced intrinsic misfolding independent of biological conditions
and interacting proteins.
Application of the limited proteolysis conformational assay to
the same protein in purified form and in biological context allowed
comparison of conformational differences in vivo and in vitro. Prior
biophysical characterization [10] showed that deletion of F508
affects the yield of purified NBD1 refolding in vitro. To assess the
effects of mutations on the stability of the domain we analyzed the
thermal stability of the purified NBD1 proteins that were used for
limited proteolysis: while wild-type human and mouse NBD1
thermal stability were different, the decrease in melting temper-
ature due to the absence of F508 was similar in both cases
(Figure 3A).
Only I539T but not G550E suppresses the DF508
phenotype in NBD1
As the folding defect in DF508 CFTR arose in NBD1, we asked
whether this defect could be rescued in NBD1 as well. Teem and
colleagues identified two suppressor mutations (G550E, I539T) in
NBD1 that were located in the same subdomain as F508
(Figure 3B), and that each partially rescued DF508 CFTR from
the ER [19]. We therefore examined whether the I539T mutation
stabilized purified DF508 NBD1 (Figure 3A), and found that
I539T completely rescued thermal stability of DF508 NBD1, and
improved stability of wild-type NBD1 as well. Another interesting
aspect to residue 539 is that it varies between isoleucine and
threonine in different species (Figure 3C), with Ile the residue in
man and Thr the residue in mouse, suggesting that mice in
principle carry an intragenic suppressor to the DF508 mutation.
Indeed, thermal stability curves of mouse NBD1s were indistin-
guishable from those of the corresponding human I539T NBD1s
(Figure 3A).
To establish whether the in vitro suppression of DF508 by I539T
leads to improved in vivo stability of NBD1, we expressed wild-type
and DF508 NBD1 with or without suppressor mutation I539T in
CHO cells, and measured each protein’s half-life (Figure 2E). For
comparison we included the G550E suppressor mutation. The two
mutations exerted very different effects in that G550E did not
affect stability of wild-type or DF508 NBD1, while I539T
measurably stabilized the domain (Figure 3D). The amount of
DF508 NBD1 remaining after 4 hours of chase improved from
10% to ,60% by insertion of I539T, whereas wild-type NBD1
improved from 30% to ,60%, consistent with the improved
melting temperatures we measured. We concluded that the I539T
suppressor mutation rescues the thermodynamic and biological
stability of DF508 NBD1.
I539T but not G550E fully restores the conformational
defect in DF508 NBD1
To establish whether the improved stability of the I539T
mutant was due to rescued conformation, we in vitro translated
wild-type and DF508 NBD1 with or without suppressor mutations
and monitored changes in proteolytic digestion (Figure 4A). Again,
I539T, but not G550E, caused a dramatic effect on the proteinase
K digest, particularly detectable at 5 mg/ml. Notably, the I539T
mutation restored the wild-type NBD1 pattern in DF508: both
protease resistant bands of ,25 and 27 kDa that had been lost in
DF508 NBD1 returned upon mutation of I539 to Threonine
(Figure 4A, b). Comparing longer exposures of the 100 mg/ml
ProtK treatment of the NBD1 molecules revealed that only the
I539T mutation restored the ,17 kDa protease resistant band
that had been lost in DF508 NBD1, whereas G550E had no
measurable impact (Figure 4B, N). Performing similar limited
proteolysis experiments on purified DF508 NBD1 with or without
the I539T mutation confirmed that this suppressor mutation
specifically restored protease resistance of the 25 and 17 kDa
fragments (data not shown).
To determine whether the rescue of DF508 NBD1 occurred also
in full-length CFTR, we in vitro translated full-length wild-type and
DF508 CFTR, with or without the suppressor mutations, and
digested each sample with proteinase K. Lane quantitiation of
5 mg/ml proteinase K digests showed recovery of the ,25 kDa
proteinase K-resistant fragment (Figure 4C, b). The I539T
mutation itself slightly decreased electrophoretic mobility of NBD1
and CFTR (not shown), but also of the 25 kDa fragment,
suggesting that this fragment contained the I539T mutation. We
concluded that I539T but not G550E rescues the DF508
phenotype by completely restoring NBD1 conformation and
stability.
Because NBD1 in wild-type CFTR folds already during
synthesis [24], we asked whether NBD1 misfolding and rescue in
DF508 CFTR occurred during nascent chain elongation and co-
translational folding. During the first 30 minutes of in vitro
translation we monitor only nascent chains and thus co-
translational folding of CFTR; after this, full-length CFTR
appears [24] (Figure 5A). We harvested nascent chain populations
of wild-type and DF508 CFTR after 20 and 30 min of synthesis, as
well as full-length proteins (60 min) (Figure 5A), and subjected
them to treatment with 5 mg/ml of Proteinase K (Figure 5B).
Already in the small DF508 CFTR nascent chains synthesized
within 20 min, the ,25 kDa NBD1-related fragment was absent,
while it was present in wild-type CFTR nascent chains (Figure 5B,
cf. lanes 1 and 2). Throughout ongoing synthesis and folding of C-
terminal portions of the protein (30 and 60 min), detectable as
protease resistant bands with lower electrophoretic mobility
(Figure 5B, lanes 3–6,]), the protease sensitive conformation of
DF508 CFTR remained evident. A similar experiment was done
with I539T CFTR and DF508 I539T CFTR. Lane quantitation of
the proteolytic fragments after 30 minutes of synthesis showed a
protease resistant 25 kDa fragment for both wild-type and DF508
CFTR containing the additional I539T mutation (Figure 5C).
These results show that the NBD1 conformation that leads to
protection from limited proteolysis already formed co-translation-
ally, and that DF508 CFTR was deficient in this process but was
rescued by I539T during synthesis.
Both I539T and G550E partially restore ‘‘band C’’ levels of
DF508 CFTR. i.e. molecules that obtained complex glycosylation
in the Golgi complex [19]. Increased levels of complex
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plasma membrane (longer half-life) or improved maturation at the
ER membrane or both. We found that only the I539T suppressor
restored DF508 NBD1 domain stability suggesting that multiple
mechanisms can contribute to rescue of DF508 CFTR. To analyze
whether the I539T suppressor improved CFTR maturation like
G550E [20,21] we used a pulse-chase approach to monitor both
rate and efficiency of DF508 CFTR rescue.
Transfected HeLa cells were radioactively pulse-labeled to
follow maturation of full-length CFTR over time by using the
acquisition of complex glycans in the Golgi apparatus as a
measure of maturation. While the majority of wild-type CFTR
molecules had reached the Golgi complex after 2–4 hours
(Figure 6 upper left panel, bb,C - b a n d ) ,DF508 CFTR was
retained in the ER (Figure 6 upper right panel, b,B - b a n d )a n d
degraded by the proteasome. Introducing either G550E or
I539T within DF508 CFTR partially countered misfolding and
enhanced export from ER to Golgi (Figure 6). The I539T
suppressor was much more effective than G550E in rescuing
DF508 CFTR: the majority of CFTR molecules now reached
the Golgi complex, whereas some loss of signal still occurred for
G550E, implying some residual degradation. On top of this
rescue of DF508 CFTR, both suppressor mutations also
increased maturation rate of wild-type CFTR molecules: they
reached the Golgi complex faster and, 2 hours after synthesis,
almost no core glycosylated (ER-resident) CFTR was visible
anymore. We conclude that, while both mutations rescue full-
length CFTR to the plasma membrane, the I539T mutation
rescues the DF508 phenotype within the isolated NBD1 domain
already during its synthesis whereas G550E practically bypasses
the folding defect in NBD1 and rescues via an alternative
mechanism.
Discussion
The cystic fibrosis DF508 mutation that resides in the NBD1
domain of CFTR directly affects stability of this domain in vitro.
We here show that mutant NBD1 not only lacks thermal stability
but also cell biological stability, as the isolated domain was
degraded faster than wild-type NBD1 in intact cells. We found,
using limited proteolysis, that DF508 CFTR misfolded already co-
translationally, as soon as the NBD1 domain had been
synthesized. This primary folding defect arose independent of
other domains and other cellular components. The I539T
suppressor mutation but not G550E in the same subdomain
rescued the defect and restored NBD1 conformation to wild-type,
Figure 3. Stability of DF508 NBD1 is restored by introducing I539T. (A) Thermal denaturation of NBD1 variants, as indicated in the Figure.
Bars represent average (n=3) melting temperatures (TM), error-bars are SD. (B) Crystal structure of mouse NBD1 (1R0W). F508, T539 and G550 are
shown in blue, and ATP in yellow. (C) Aligning CFTR sequences of several species revealed that an isoleucine or threonine on position 539 is species
dependent. CFTR sequences are from Oryctolagus cuniculus (rabbit), Xenopus laevis (frog), Rattus norvergicus (rat), Mus musculus (mouse), Homo
sapiens (human), Pan troglodytes (chimpanzee), Equus caballus (horse), Canis lupus familiaris (dog), Mustela putorius furo (ferret), Sus scrofa (pig). (D)
CHO cells transiently expressing NBD1 with and without indicated mutations were pulse-labeled for 5 minutes and chased for 4 hours as in Figure 2E.
The percentage of labeled NBD1 present after 4 hours of chase was quantified (n=3, data represented 6 SEM).
doi:10.1371/journal.pone.0015458.g003
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target for therapeutic intervention in cystic fibrosis.
Co-translational folding defect
We studied the earliest folding events of DF508 CFTR at the
ER membrane and found that the folding defect induced by
deletion of F508 arose co-translationally, immediately upon
synthesis of NBD1. Our data suggest that the recognition that
leads to degradation of DF508 CFTR molecules already occurs at
the time of NBD1 synthesis and before downstream domains are
being synthesized. This is consistent with the co-translational
ubiquitination of CFTR [26], but also with the many chaperones
that indeed recognize this DF508 NBD1 folding defect, such as
Hsc70/Hdj-2, which bind a CFTR MSD1-NBD1 fragment twice
as much when F508 is missing [27]. Knockdown of, or
displacement from the Hsp90 co-chaperone Aha1 restores plasma
membrane levels of DF508 CFTR [28,29]. By keeping CFTR
molecules in a soluble state [30] the chaperones suppress
aggregation of NBD1 [27,31] until RMA1 or CHIP are recruited
to facilitate co- or post-translational degradation respectively
[32,33]. The NBD1 domain emerges not only as the primary site
for misfolding but also as the first domain in DF508 CFTR that is
recognized and targeted for degradation.
NBD1 as primary site for misfolding in DF508 CFTR
The DF508 mutation directly affected the isolated NBD1
domain. NBD1 showed this change not only when purified, but
also when expressed in cells, and alone or as part of full-length
DF508 CFTR, in nascent chains or in C-terminally truncated
chains that contained NBD1. Limited proteolysis is based on the
relative protease resistance of folded domains compared to
unstructured or misfolded regions. In our experiments relative
Figure 4. Rescue of NBD1 conformation by the I539T suppressor mutation. (A) Wild-type and DF508 NBD1 (top panel) mRNAs containing
the G550E (middle panel) or I539T (bottom panel) mutation were in vitro translated in the presence of
35S-labeled methionine and cysteine and
analyzed by 15% SDS-PAGE after proteinase K treatment. Asterisk indicates the 27 kDa fragment, arrowhead indicates the 25 kDa fragment. (B)
Longer exposure of the 100 mg/ml proteinase K digest of in vitro translated NBD1, from same experiment as shown in B, showing the rescue of the
17 kDa band by the I539T but not by the G550E mutation. Gel lanes are aligned on the 25 kDa bands. (C) CFTR molecules containing the indicated
mutations were in vitro translated, analyzed using 12% SDS-PAGE and lanes were quantified as described in Figure 1B. The arrowhead indicates the
25 kDa fragment, which has slightly decreased mobility when the I539T mutation is present.
doi:10.1371/journal.pone.0015458.g004
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showed that the same proteolytic cleavage sites were used but had
become more accessible in mutant protein. This points to a change
in stability of NBD1 and not necessarily a large change in
conformation.
Our data is consistent with previous in vitro folding studies on
isolated wild-type and DF508 NBD1 [10,13,14], which show that
DF508 has a measurable effect on the yield with which the isolated
NBD1 domain folds. An elaborate mutagenesis analysis showed
that the lack of the backbone due to F508 deletion results in this
inefficient folding of NBD1 [10] which is in line with our work
showing that the primary folding defect of DF508 CFTR is within
NBD1. However human DF508 NBD1 crystal structure was
highly similar to the structure of wild-type NBD1 [34,35,36]. Yet,
to purify and crystallize DF508 NBD1 required either suppressor
mutations or deletion of flexible loops.
Where in NBD1 is the defect?
Proteolytic digests of purified NBD1 revealed two major
protease resistant fragments, one of ,25 kDa and a second
smaller fragment of ,17 kDa. The 25 kDa fragment represents
the bulk of the ‘‘core domain’’ of NBD1 lacking both N- and C-
termini, and the 17 kDa fragment is a part of this. The same core
domain was found in the crystal structure of human NBD1 [34].
Antibodies recognizing the core of the NBD1 sequence or the
entire domain (660, Mr Pink & 7D12) specifically recognized both
fragments, while antibodies mapped to the N-terminal epitopes of
NBD1 (10B6. 2 & 3G11) or the far C-terminus (G449) did not.
The N- and C-termini of NBD1 thus were removed first by the
proteases, independent of the DF508 mutation, which explains
why wild-type and mutant NBD1 disappeared at similar protease
Figure 5. Co-translational misfolding and rescue of NBD1. (A) After 5 min pre-warming the translation mix, we added
35S-methionine and
followed CFTR synthesis in the SP-cell system for 10–60 min. Analysis using 10% SDS-PAGE directly visualized CFTR nascent chain elongation with
time. Full-length DF508 CFTR (,) first appeared after 30 min of translation, ‘‘X’’ indicates persistent unfinished nascent chains. (B) Wild-type and
DF508 nascent chains were translated in vitro and harvested after 20, 30, or 60 min of synthesis. All nascent chains were subjected to increasing
proteinase K concentrations and proteolytic fragments were separated by 12% SDS-PAGE. In the 5 mg/ml proteinase K treatment shown here, the
NBD1-related 25 kDa fragment is marked by an arrowhead. The bracket indicates increased protease resistance of CFTR domains as a result of
nascent chain elongation. (C) Similar experimental conditions as in B but with the I539T mutation in wild-type and DF508 CFTR background. Nascent
chains were harvested after 30 min of synthesis and protease resistant fragments were quantified as in Figure 1B. Arrowhead indicates the NBD1-
related 25 kDa fragment.
doi:10.1371/journal.pone.0015458.g005
Figure 6. Suppressing the DF508 phenotype in vivo. HeLa cells
transiently expressing CFTR with the indicated mutations were pulse-
labeled with
35S-methionine and cysteine for 15 minutes and chased for
the indicated times. CFTR molecules were immunoprecipitated from
radiolabeled lysate using polyclonal antibody directed against the R-
domain (G449). Samples were analyzed using 7.5% SDS-PAGE. The
arrowhead indicates the ER oligomannose form (B-band) and the
double arrowhead indicates complex glycosylated CFTR (C-band).
doi:10.1371/journal.pone.0015458.g006
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cleavage sites likely reside in RI and RE as they are mobile
[37], and the N-terminal strand may stay associated until
denaturation by SDS, although the core domain does not need
RI and RE for stability [36]. Both 25 kDa and 17 kDa fragments
did show increased protease susceptibility in the DF508 back-
ground, which was rescued completely by the I539T suppressor
mutation, not only in terms of protease susceptibility but also its in
vivo stability and function.
In full-length CFTR we detected the ,25 kDa core NBD1
fragment but not the ,17 kDa fragment, most likely because of its
weaker radiolabeling (considering the lower number of methio-
nines and cysteines in this fragment), or because of the overlap in
gel with other fragments deriving from other CFTR domains.
Reverting the DF508 phenotype
While the I539T mutation rescued NBD1, G550E hardly
affected the isolated DF508 NBD1 domain. Still, both suppressor
mutations rescued full-length CFTR from its retention in the ER
and allowed CFTR channel activity at the cell surface [19,20].
This implies that there is more than one route to rescue, either by
correcting the primary defect in NBD1 or by bypassing this
primary defect and rescuing domain assembly downstream [11].
After (mostly co-translational) folding of the individual domains
[24], these domains need to assemble. Studies on interacting
domains [38,39,40] and molecular modeling [7,8,9] have drawn a
clear picture of the domain interactions in CFTR, with the 2
MSDs and the 2 NBDs all 4 interacting with each other, similar to
the homologue Sav1866 [41]. In particular the assembly of NBD1
with the 4
th intracellular loop of CFTR (ICL4) in MSD2 has
received much attention [8] and is likely to be the process
immediately downstream of NBD1 and MSD2 domain folding.
The F508 deletion was shown to increase protease susceptibility
also of the MSD1 and NBD2 domains, suggesting additional
important domain-domain interactions for folding [11,12].
Where G550E does not measurably rescue NBD1 misfolding, it
does rescue CFTR functioning and therefore is likely to rescue at
least one of the downstream domain assembly steps. The G550E
mutation is located in the highly conserved ABC transporter
signature motif of NBD1 (LSG
550GQ) and, according to the
Sav1866 homology model [8], is in close proximity to NBD2. The
relevance of this is unclear though, as stabilization of the NBD1-
NBD2 dimer [42] does not rescue DF508 CFTR maturation [43].
While G550E only slightly increases steady state plasma
membrane levels of DF508 CFTR, it does enhance CFTR
mediated chloride currents [19] and restores CFTR channel
activity by increasing the duration of channel opening and thereby
open probability (Po) [20].
The I539T mutation, by contrast, increases chloride channel
activity at the plasma membrane (Eric J. Sorscher, Birmingham,
personal communication) by increasing the number of CFTR
molecules at the cell surface [19] (and Gergely Lukacs, Toronto,
personal communication). Complete rescue of NBD1 folding
appeared, in spite of the profound effect on CFTR maturation,
insufficient for full functional rescue of the CFTR molecule,
suggesting that the DF508 NBD1 still was hampered in some
domain-domain interactions. The crystal structure of NBD1 and
the structural model of CFTR provides no obvious hint towards
the molecular mechanism of rescue by the I539T mutation.
Correction of the cystic fibrosis defect
Partial rescue of CFTR release from the ER and (hence) of its
function may be sufficient for rescue from CF disease. While
estimates vary, an increase of 10% CFTR channel activity on the
plasma membrane has been predicted to be the lower limit
sufficient to relieve the CF clinical phenotype [44]. Alignments of
members of the ABCC (ABC-transporter subfamily of CFTR)
revealed that most members of the ABCC family have a 539T
suggesting an evolutionary benefit to having a threonine in this
position rather than an isoleucine. Mice also have this intragenic
suppressor. We here show that the 539 residue completely
accounted for the stability difference between mouse and human
purified NBD1, and predict that the recently generated CF ferret
[45] and CF pig [46] may be better model organisms for some of
the clinical phenotypes in cystic fibrosis.
Materials and Methods
Cell lines
HT1080 cells (ATCC) were grown in DMEM supplemented
with 8% fetal calf serum. The human cervical carcinoma cell line
HeLa (ATCC) was grown in MEM supplemented with 10% fetal
calf serum and non-essential amino acids and Chinese hamster
ovary cells (CHO) were cultured in a-MEM supplemented with
8% fetal calf serum. All cells were cultured in media containing
100 U/ml each of penicillin and streptomycin and 2 mM
Glutamax I and kept in humidified incubators at 37uC containing
5% CO2. All cell culture media and reagents were obtained from
Invitrogen.
Antibodies and purified protein
G449 [24,47] polyclonal antisera directed against the CFTR R-
region (residues 693–716) were generously provided by Drs Angus
Nairn (Rockefeller University, New York NY, USA) and Hugo de
Jonge (Erasmus University, Rotterdam, The Netherlands). Mr
Pink polyclonal rabbit antiserum was raised by the Braakman lab
against purified human NBD1 and characterized to recognize all
forms of NBD1, folded, misfolded and denatured. The mouse
monoclonal 7D12 was raised by the Thomas lab against purified
human NBD1. The same antigen was used by Dr. Bill Balch
(Scripps Research Institute, La Jolla CA, USA) who generously
provided 3G11 rat monoclonal antibody and by Dr. Eric Sorscher
(Gregory Fleming James Cystic Fibrosis Research Center,
Birmingham Alabama, USA), who generously provided 10B6.2
mouse monoclonal antibody. All purified NBD1 was supplied by
the Thomas lab [48]. Epitope mapping was done by Dr Gergely
Lukacs: Mr Pink recognizes various epitopes in NBD1, 7D12 sees
epitope 531–540, 3G11 sees epitope 396–405, and 10B6.2
recognizes epitope 399–408). All information concerning protein
and antibodies can be found at http://www.cftrfolding.org/
reagentrequests.htm.
Cloning and constructs
The C-terminally truncated hCFTR proteins used in this study
were constructed as described before [24]. For transfections
hCFTR constructs were subcloned into the pcDNA3 vector using
NotI and XhoI (Fermentas). The DF508 phenotype was
introduced in pBS hCFTR 642X (N-NBD1) and pBS CFTR
837X (N-R) using XbaI and SphI (New England Biolabs). cDNA
of hNBD1 (T
389-G
673) was cloned by PCR using primers (forward:
59-GGAATTCCCCGGGGCCACCATGACTACAGAAGTAG-
TGATGGAG-39; reverse: 59-GCGATATCCTATCCTTCTAA-
TGAGAAACGGTG-39), ligated into pJET vector and subcloned
to pcDNA3 vector using EcoRI and EcoRV (Fermentas). The
deletion of F508 and the reverting mutations G550E and I539T
were introduced both in full- length CFTR and NBD1 by side
directed mutagenesis using primers (amino acid change under-
lined, I539T: 59-CCAAGTTTGCAGAGAAAGACAATACCG-
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TGGAATCACACTGAGTGAGGGTCAACGAGCAAGAATT-
TCTTTAGC-39 DF508: 59-GGCACCATTAAAGAAAATATC-
ATTGGTGTTTCCTATGATGAATATAG-39) and all con-
structs were sequence verified.
Transient expression
HeLa and CHO cells were seeded in 8.5 cm
2 dishes to reach
50–60% confluency on the day of transfection. To transfer DNA
into cells we used a linear 25 kDa polymer polyethylenimine (PEI)
dissolved in water to 1 mg/ml, pH adjusted to 7.4, and filtered
sterilized (Polysciences). The DNA/PEI complexes were pre-
incubated for 15 minutes at room temperature in 150 mM NaCl
and added to cells 20 hours before experiments.
Pulse-chase analysis
Cells were transfected with pcDNA3-CFTR or pcDNA3 -
NBD1 constructs containing indicated mutations. The pulse-chase
assay was performed as described before [49]. Briefly, HeLa or
CHO cells were starved for 15–25 min in MEM without cysteine/
methionine (ICN biomedicals) supplemented with Glutamax I
(InVitrogen). The HeLa cells expressing full-length CFTR were
pulse-labeled for 15 min with
35S-methionine and cysteine
(60 mCi/dish, Easytag
TM Express Protein Labeling Mix, Perkin
Elmer) and CHO cells expressing NBD1 were pulse-labeled for
5 min (30 mCi/dish). CFTR was immunoprecipitated from the
radiolabeled non-denaturing lysate (20 mM MES, 50 mM Tris-Cl
pH 7.4, 100 mM NaCl, 1% Triton X-100, 1 mM PMSF, 10 mg/
ml each of chymostatin, leupeptin, antipain, and pepstatin) using
G449 antiserum directed against the R-domain, and NBD1 was
immunoprecipitated in a similar manner using polyclonal
antiserum directed against the NBD1 domain (Mr Pink). The
samples were analyzed on SDS-PA gel (7.5% for full-length
CFTR, 15% for NBD1), prepared for fluorography, dried, and
exposed to film (Kodak Biomax MS).
In vitro translation in the presence of semi-permeabilized
cells
This method [50] was adapted to study CFTR nascent chain
elongation as described before [24]. In brief, NBD1 or CFTR
mRNA was in vitro translated in rabbit reticulocyte lysate
(Promega) using
35S-methionine and cysteine and for translation
of full-length CFTR in the presence of freshly prepared semi-
permeabilized (SP) HT1080 cells. After incubation at 30uC, the
translation was stopped by adding ice-cold KMH buffer (110 mM
KOAc, 20 mM HEPES pH 7.2, 2 mM MgOAc) containing
1 mM cycloheximide. The SP-cells were spun down at 4uC,
washed with KHM buffer and lysed in KHM containing 1%
Triton X-100. Either 2x Laemmli sample buffer was added (final
concentrations 200 mM Tris-HCl pH 6.8, 3% SDS, 10%
glycerol, 1 mM EDTA, 0.004% bromophenol blue) for analysis
on SDS-PAGE or samples were subjected to limited proteolysis.
Limited proteolysis
Folding of CFTR and NBD1 was assayed through protease
susceptibility. Immediately after in vitro translation, proteins were
subjected to increasing concentrations of TPCK-trypsin (Sigma) or
Proteinase K (Roche) as described before [24]. Experiments were
performed using different batches of Proteinase K at different
storage conditions, which resulted in minor variations in
proteolytic patterns between experiments. For each experimental
setup, a range of protease concentrations was used and proteolytic
patterns representative of at least 3 experiments were shown.
Lane quantitation
Exposed films containing corresponding proteolytic patterns
loaded side by side in 12% SDS-PA gel, were scanned using a
GS710 densitometer (Biorad). Total lane quantitation was done to
determine relative intensities of protease resistant fragments using
Quantity One software (Biorad).
Temperature melts of isolated NBD1
Thermal denaturation was measured by monitoring Turbidity
(aggregation) at 300 nm of 5 mM NBD1-CFTR in Buffer M
(50 mM Tris-HCl, 150 mM NaCl, 5 mM MgCl2, 2 mM ATP,
pH 7.6). Turbidity was measured every 0.5uC, rate of temperature
increase was 0.5uC/min. Melting Temperature (TM) was deter-
mined by taking the second derivative.
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